Skip to main content

The Money Overview

Specialty medicines from the European Union, Japan, India and the United Kingdom entered the United States tariff-free from September 29

The United States stopped charging import duties on a defined class of specialty medicines from the European Union, Japan, India and the United Kingdom at 12:01 a.m. Eastern on September 29, 2026, the same day a 100 percent baseline tariff on patented pharmaceuticals reached most drugmakers. The zero rate sits inside a Commerce Department implementation notice rather than in a new tariff schedule, and it covers orphan drugs, plasma-derived therapies, gene and cell therapies and several other categories. The four jurisdictions named in the headline are not alone, though: the notice lists 19 entries, and the real question is which products and which importers clear the conditions attached to the zero.

The notice was published in the Federal Register on September 23 by the Bureau of Industry and Security, but publication and effect are separate dates. Commerce set September 29 as the moment the tariff adjustment began to apply, which also happens to be the date the proclamation behind it brought the 100 percent rate to every company outside a first group that was covered from July 31. Shipments entering before that minute fell under the earlier arrangements, so the date is a legal line in customs entries, not a news date.

What the zero rate covers and who is on the list

The notice states that the listed jurisdictions “are eligible for the tariff adjustment described in clause 3(d) of Proclamation 11020.” The full roster is Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, the Republic of Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam. Read literally, the European Union, Japan, India and the United Kingdom are four of 19 entries, and the notice publishes no count of jurisdictions, partly because the European Union entry stands for 27 member states and Switzerland and Liechtenstein share a single line.

The product definition is narrow and itemised. Specialty pharmaceuticals under the notice include drugs whose approved indications are all designated orphan, nuclear medicines, plasma-derived therapies, fertility drugs, cell therapy products, gene therapy products, antibody drug conjugates, medical countermeasures against chemical, biological, radiological and nuclear threats, and animal health products. A cancer antibody conjugate shipped from Japan therefore qualifies, while an ordinary patented tablet from the same plant does not. The rate for qualifying goods is zero on an ad valorem basis, measured against the 100 percent baseline that applies to other patented drugs.

Tariff notices like this one tend to be amended through follow-on guidance, so a short note when the next Commerce update lands is the simplest way to keep the picture current.

Get the next update free → Free from RetireShield. Unsubscribe anytime.

Eligibility is not automatic for every shipment from a listed country. Clause 3(d) of the proclamation ties the zero rate to products of a jurisdiction that has a current or forthcoming trade and security framework agreement with Washington, or to products that meet an urgent United States health need and win Commerce approval through a submission sent to a dedicated pharma232 mailbox at BIS. The notice names Stephen Astle, director of the Defense Industrial Base Division in BIS’s Office of Strategic Industries and Economic Security, among the officials responsible for the process.

For readers following a prescription cost, the practical question is whether an imported orphan or plasma drug that now enters duty-free is cheaper at the pharmacy, and the record does not answer it. A tariff of zero removes a cost that a 100 percent rate would have added; it does not oblige a manufacturer to lower a list price, and nothing in the notice touches insurer formularies or Medicare payment. The reported effect is on landed cost, not on what patients or plans pay.

How the baseline tariff in Proclamation 11020 works

The legal engine is Proclamation 11020, signed by President Donald Trump on April 2, 2026, which imposes a 100 percent ad valorem duty on patented pharmaceuticals and the ingredients used to make them. The text cites a Commerce Department finding that pharmaceuticals and active pharmaceutical ingredients “are being imported in quantities threatening national security,” and notes that roughly 53 percent of patented pharmaceutical products distributed in the United States are produced abroad while only about 15 percent of patented active ingredients are made domestically.

The same proclamation builds several discounts under the 100 percent figure. Companies that commit to onshoring pay 20 percent at first, rising to 100 percent on April 2, 2030. Under clause 3(c), imports from the European Union, Japan, South Korea and Switzerland and Liechtenstein are charged 15 percent, and the United Kingdom 10 percent, with a possible move to zero under a future agreement. Generic pharmaceuticals and their ingredients are carved out entirely, since clause 5 says they “shall not be subject to tariffs pursuant to section 232 at this time.”

Layering the pieces shows why the headline’s four names are not interchangeable. A specialty product from the European Union or Japan is zero-rated under clause 3(d), while a conventional patented drug from the same jurisdiction pays 15 percent. India is not named in the proclamation’s reduced-rate clause at all, so a patented non-specialty product from an Indian plant would meet the full 100 percent baseline, whereas an Indian-made gene therapy or plasma product could go in free.

Which importers and shipments clear customs

Two timelines run side by side. The proclamation text on the White House site applies the tariff to companies listed in an annex starting July 31, 2026, and to every other company from September 29, 2026. For an importer outside the annex, September 29 was therefore the first day both the 100 percent baseline and the specialty zero rate became operative, and customs brokers had to tell the two apart on each line of an entry.

The conditions are where disputes are most likely to arise. A product has to fit one of the enumerated specialty categories, come from a listed jurisdiction that has or is negotiating a framework agreement, or else be approved on the urgent-need route. An orphan designation covering only some indications would not satisfy the all-indications test, and mixed-use ingredients raise a classification question the notice leaves to Commerce.

What the official record has not yet shown is volume. Neither the notice nor the proclamation reports how many shipments or what dollar value of drugs now enters at zero, so any claim about savings to manufacturers or to health systems rests on inference. The measurable fact is the rule itself: a 19-entry eligibility list, a nine-category product definition, and a start time of 12:01 a.m. on September 29.

Reading the notice before relying on the zero rate

The controlling text is the Federal Register notice from the Bureau of Industry and Security, which is free to read and carries the jurisdiction list, the category definitions and the submission route for urgent-need requests. Anyone checking a specific product should match its approved indications against the orphan, plasma, cell and gene, fertility and nuclear categories first, and only then look at the country of production, because the category test is the one that most often fails.

The unresolved point is how the 19-entry list will change. The proclamation allows the United Kingdom’s 10 percent rate to fall to zero under a future agreement, and the notice’s conditions favour jurisdictions with current or forthcoming trade and security frameworks. Each new framework would widen the roster, and each change would arrive through another notice with its own effective date, which is the date a reader should check rather than the publication date.

More Financial Reading

This article was produced with AI assistance and reviewed by The Money Overview’s editorial team.

Avatar photo

Daniel Harper

Daniel is a finance writer covering personal finance topics including budgeting, credit, and beginner investing. He began his career contributing to his Substack, where he covered consumer finance trends and practical money topics for everyday readers. Since then, he has written for a range of personal finance blogs and fintech platforms, focusing on clear, straightforward content that helps readers make more informed financial decisions.​